Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug By Investing.com
Update: 2025-11-03
Description
Benitec Biopharma's experimental gene therapy, BB-three-oh-one, has shown promising results in treating Oculopharyngeal Muscular Dystrophy with dysphagia, a rare disease causing severe swallowing problems. After positive interim results from the first trial cohort, the company received Fast Track status from the FDA, potentially speeding up development and review. With Orphan Drug Designation in the US and Europe, Benitec is planning to finalize the pivotal study design in 2026, bringing hope to patients and families awaiting breakthroughs.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
